Cytokinetics EVP Fady Malik sells $239k in company stock

Cytokinetics' Executive Vice President of Research & Development, Fady Ibraham Malik, sold 3,500 shares of the company's common stock on September 22, 2026, for a total value of $239,015. The stock sale came as part of a filing where Malik acquired 3,500 shares through non-qualified stock options at an exercise price of $7.80 per share, resulting in a total value of $27,300.

Following these transactions, Malik currently holds 153,902 shares of Cytokinetics common stock. In addition, Malik benefits from owning 23,386 non-qualified stock options. Cytokinetics reported strong second-quarter sales of Myqorzo, amounting to $25.3 million, which exceeded Bloomberg consensus estimates by 65.2% during its initial full quarter on the market.

This positive result led Barclays to raise its price target on Cytokinetics shares to $110, while maintaining an Overweight rating.